WHO vaccine-preventable diseases: monitoring system. 2020 global summary

Last updated 15-July-2020 (data as of 12-October-2020)
Next overall update End 2020
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 65'7601 Infant (under 12 months) mortality rate: 62
GDP / capita (US$): 65'2811 Child (under 5 years) mortality rate: 72

Population data in thousands3

  2019  2018  2017  2016  2015  2000  1990  1980 
Total population 329'065  327'096  325'085  323'016  320'878  281'711  252'120  229'476 
Births 3'932  3'912  3'899  3'894  3'900  3'961  3'952  3'433 
Surviving infants 3'910  3'890  3'877  3'871  3'877  3'933  3'914  3'390 
Pop. less than 5 years 19'604  19'512  19'475  19'595  19'935  19'565  19'241  16'580 
Pop. less than 15 years 61'039  61'197  61'306  61'448  61'685  61'139  54'646  52'030 
Female 15-49 years 74'685  74'392  74'138  73'900  73'662  71'270  66'029  58'609 

Number of reported cases

(Click for retrospective incidence data for United States of America)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles***
ChartChart
  375  120  85  188  85  27'786  13'506 
Mumps
ChartChart
  2'515  6'109  6'369  1'308  323 
Pertussis
ChartChart
  15'609  18'975  17'972  20'679  7'867  4'570  1'730 
Polio*
ChartChart
 
Rubella***
ChartChart
  176 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  33  34  30  35  64  95 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.
*** For 2019, if a country did not submit a joint reporting form, measles and rubella cases were sourced from data reported through the monthly surveillance data available from:
https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles_monthlydata/en/

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for United States of America)
Vaccine year result method % card seen                                                
BCG         
DTP1          97  97  98  98  98  99* 
DTP3          94  94  95  95  95  94  96 
IPV1          97  96  97  97  97 
HepB_BD          67  66  64  64  72 
HepB3          91  91  93  93  92  90 
Hib3          91  92  93  93  93  93 
JapEnc         
MCV1          90  92  92  92  92  91  86 
MCV2          95  94  94  85 
MenA         
PCV1          96  97  97  97  97 
PCV2          95  95  95  96  95 
PCV3          92  92  93  93  93 
Pol3          93  93  94  94  93  90  95 
Rota1          89  88  88  88  87 
RotaC          74  73  73  73  72 
RCV1          90  92  92  92  92 
TT2plus          55  54  50  49 
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid July 2021

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for United States of America)
DTP1
ChartChart
  97  97  98  98  98  99  96  98 
DTP3
ChartChart
  94  94  95  95  95  94  90  96 
HepB3
ChartChart
  91  91  93  93  92  90 
HepB_BD
ChartChart
  67  66  64  64  72 
Hib3
ChartChart
  91  92  93  93  93  93 
IPV1
ChartChart
  97  96  97  97  97 
MCV1
ChartChart
  90  92  92  92  92  91  90  86 
MCV2
ChartChart
  95  94  94  94  93  85 
PCV3
ChartChart
  92  92  93  93  93 
Pol3
ChartChart
  93  93  94  94  93  90  85  95 
RCV1
ChartChart
  90  92  92  92  92  91  90  86 
RotaC
ChartChart
  74  73  73  73  72 

Click to download WHO-UNICEF coverage estimates data for PAB time series.
Click to download WHO-UNICEF coverage estimates data for HPV time series.

Number of districts in the country 3'143  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2019 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
CHOLERA 18 years; Yes
DT 2, 4, 6 months; 4 years; Yes contraindication to pertussis component
DTaP 2, 4, 6, 15 months; 4 years; Yes
DTaPHepBIPV 2, 4, 6 months; Yes
DTaPHibHepBIPV 2, 4, 6 months; Yes Planned introduction in 2021
DTaPHibIPV 2, 4, 6, 15 months; Yes
DTaPIPV 4 years; Yes
HepA_Adult 19 years; +6 months; Yes
HepA_Pediatric 12, 18 months; Yes
HepB_Adult 19 years; +1, +4 months; Yes
HepB_Pediatric birth; 1, 6 months; Yes
Hib 2, 4, 6, 12 months; Yes
HPV 11-12 years; +6 months; Yes females and males; if 1st dose is administered at <15 years and no risk groups then x2 doses with interval 6-12 months; if the 1st dose is administered >=15 years or for risk groups x3 doses with an interval of 0, 1, 6 months
Influenza_Adult >=18 years; Yes and adults with chronic conditions, older persons, pregnant women, health care workers, other risk groups
Influenza_Pediatric >=6 months; Yes and children with chronic conditions
IPV 2, 4, 6 months; 4 years; Yes
JE_Inactd 2, +1 months; Yes
MenACWY-135 conj 11, 16, +5 years; Yes
MenB 10 years; +1, +6 month; Yes high-risk groups for invasive meningococcal disease
MMR 12 months; 4 years; Yes
MMRV 12 months; 4 years; Yes
Pneumo_conj 2, 4, 6, 12 months; Yes
Pneumo_ps 65 years; Yes
Rotavirus 2, 4, 6 months; Yes 2 or 3 doses depending on vaccine/risk group
Td 21 years; Yes
Tdap 11 years; Yes Updated JRF received 24/Jun/2020
Typhoid_ps 2 years; Yes at-risk persons
Varicella 12, 15 months; Yes
YF 9 months; Yes at-risk persons
Zoster 50 years; +2 months; Yes

Immunization indicators

Indicator Expected answer 2019  2018  2017  2016  2015  2014  2013 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR       No  No     
What years does the MYP cover? number             Yes 

System performance

Total Nº districts in country number              
Nº districts with DTP3 coverage >=80% number
% of districts with DTP3 coverage >=80% From 0 to 100%              
Nº districts with measles (MCV1) coverage >=95% number  
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes      Yes       
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes      Yes      Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes   

Sources

 1  "The 2019 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  UN Inter-agency Group for Child Mortality Estimation (https://childmortality.org/data)  
 3  "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.